Stomach News and Research

RSS

Results of Creutzfeldt-Jakob disease research in people who received human growth hormone from cadavers

The largest study of its kind, designed to track the development of Creutzfeldt-Jakob disease in people who received human growth hormone from cadavers, has found that the vast majority of those who received the hormone did not contract the fatal condition. However, some recipients (26 out of approximately 7,700) did develop the disease.

7 Apr 2004

Women with a history of pre-eclampsia are at increased risk of cancer

Women with a history of pre-eclampsia are at increased risk of cancer, particularly cancers of the stomach, breast, ovary, lung and larynx, according to a Columbia University study recently published by the British Medical Journal. Researchers studied 37,000 women in western Jerusalem, Israel, who delivered babies in three large hospitals between 1964 and 1976.

7 Apr 2004

Fluorescent molecule used to examine real time chemical reactions that result in smooth-muscle contraction

Smooth muscle, found in the walls of blood vessels and in internal organs such as lungs, stomach and the bladder, contracts as the end result of a series of chemical reactions. In a new study, UT Southwestern researchers report that one set of chemical reactions resulting in the contraction of the smooth-muscle cells is augmented by a second chemical pathway that kicks in when the first pathway is limited.

5 Apr 2004

Oral medication for diabetes a step closer

University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.

26 Mar 2004

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004

Bacteria Live in the Esophagus!

The esophagus isn't merely a tube for food traveling from the mouth to the stomach, it also provides an environment for bacteria to live, according to a new study by NYU School of Medicine scientists that overturns the general belief that the esophagus is free of bacteria.

22 Mar 2004